Kui Jiang

876 total citations
23 papers, 330 citations indexed

About

Kui Jiang is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Kui Jiang has authored 23 papers receiving a total of 330 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pulmonary and Respiratory Medicine, 11 papers in Oncology and 7 papers in Molecular Biology. Recurrent topics in Kui Jiang's work include Ovarian cancer diagnosis and treatment (7 papers), PARP inhibition in cancer therapy (5 papers) and Advanced Breast Cancer Therapies (3 papers). Kui Jiang is often cited by papers focused on Ovarian cancer diagnosis and treatment (7 papers), PARP inhibition in cancer therapy (5 papers) and Advanced Breast Cancer Therapies (3 papers). Kui Jiang collaborates with scholars based in China, United States and Australia. Kui Jiang's co-authors include Liping Fang, Yue Wang, Xiaolin Sang, Min Wang, Pixu Liu, Hailing Cheng, Zhiwei Tao, Fuwen Luo, Haojie Huang and R. Jeffrey Karnes and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

Kui Jiang

21 papers receiving 324 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kui Jiang China 10 182 98 90 66 54 23 330
Yu-Ping Liao Taiwan 10 363 2.0× 154 1.6× 217 2.4× 35 0.5× 74 1.4× 10 508
Haiyan Dai China 11 232 1.3× 75 0.8× 130 1.4× 28 0.4× 21 0.4× 22 374
ME Sherman United States 5 116 0.6× 81 0.8× 78 0.9× 19 0.3× 145 2.7× 6 348
Yunlim Kim South Korea 12 193 1.1× 59 0.6× 93 1.0× 98 1.5× 18 0.3× 24 334
Hiroe Nakamura Japan 12 182 1.0× 124 1.3× 113 1.3× 18 0.3× 29 0.5× 29 365
Weifang Zhang China 12 209 1.1× 117 1.2× 84 0.9× 49 0.7× 7 0.1× 33 355
Aušra Sasnauskienė Lithuania 10 198 1.1× 87 0.9× 91 1.0× 76 1.2× 22 0.4× 23 366
Abhilasha Sinha United States 12 188 1.0× 134 1.4× 55 0.6× 46 0.7× 8 0.1× 17 300

Countries citing papers authored by Kui Jiang

Since Specialization
Citations

This map shows the geographic impact of Kui Jiang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kui Jiang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kui Jiang more than expected).

Fields of papers citing papers by Kui Jiang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kui Jiang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kui Jiang. The network helps show where Kui Jiang may publish in the future.

Co-authorship network of co-authors of Kui Jiang

This figure shows the co-authorship network connecting the top 25 collaborators of Kui Jiang. A scholar is included among the top collaborators of Kui Jiang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kui Jiang. Kui Jiang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Diao, Yingxue, Kui Jiang, Dan Guo, et al.. (2025). Post-train black-box defense through energy-based Bayesian adversarial training. Scientia Sinica Informationis. 55(8). 1986–1986.
3.
Wu, Lingying, Xiaofan Li, Mei Feng, et al.. (2024). Efficacy and safety of enlonstobart (SG001), a PD-1 inhibitor in patients with PD-L1 positive recurrent/metastatic cervical cancer: A multicenter, single-arm, open-label, phase II study.. Journal of Clinical Oncology. 42(16_suppl). 5526–5526. 4 indexed citations
4.
Wang, Jing, Yi Huang, Jeffrey C. Goh, et al.. (2024). 716MO Efficacy and safety of sacituzumab tirumotecan (sac-TMT) plus pembrolizumab in patients with recurrent or metastatic cervical cancer. Annals of Oncology. 35. S548–S549. 4 indexed citations
5.
Wu, Xiaohua, Jing Wang, Danbo Wang, et al.. (2024). Fruquintinib plus sintilimab in treated advanced endometrial cancer (EMC) patients (pts) with PMMR status: Results from a multicenter, single-arm phase 2 study.. Journal of Clinical Oncology. 42(16_suppl). 5619–5619. 2 indexed citations
6.
Jiang, Kui, et al.. (2024). Single‐cell combined with transcriptome sequencing to explore the molecular mechanism of cell communication in idiopathic pulmonary fibrosis. Journal of Cellular and Molecular Medicine. 28(12). e18499–e18499. 2 indexed citations
7.
Wu, Xiaohua, Jihong Liu, Jing Wang, et al.. (2024). 453 Senaparib maintenance in newly diagnosed advanced ovarian cancer: FLAMES study. A36–A36. 1 indexed citations
8.
9.
Wang, Yue, et al.. (2022). The role of ferroptosis in prostate cancer: a novel therapeutic strategy. Prostate Cancer and Prostatic Diseases. 26(1). 25–29. 22 indexed citations
10.
Wang, Min, Xiaolin Sang, Pixu Liu, et al.. (2022). Phenethyl Isothiocyanate Enhances the Cytotoxic Effects of PARP Inhibitors in High-Grade Serous Ovarian Cancer Cells. Frontiers in Oncology. 11. 812264–812264. 9 indexed citations
11.
Wang, Yue, et al.. (2022). An Effective Hormonal Therapy for a Patient with Estrogen Receptor 1 (ESR1)-Amplified Metastatic Ovarian Cancer: A Case Report. OncoTargets and Therapy. Volume 15. 643–649. 5 indexed citations
12.
An, Fan, Xiuying Wang, Jieli Yuan, et al.. (2021). Lactobacillus spp. create a protective micro-ecological environment through regulating the core fucosylation of vaginal epithelial cells against cervical cancer. Cell Death and Disease. 12(12). 1094–1094. 37 indexed citations
13.
Yu, Zhe, et al.. (2021). Efficient Everolimus Treatment for Metastatic Castration Resistant Prostate Cancer with AKT1 Mutation: A Case Report. OncoTargets and Therapy. Volume 14. 5423–5428. 1 indexed citations
14.
15.
Zu, Guo, et al.. (2019). Two-dimensional versus three-dimensional laparoscopic gastrectomy in surgical efficacy for gastric cancer: a systematic review and meta-analysis. Clinical & Translational Oncology. 22(1). 122–129. 7 indexed citations
16.
Tao, Zhiwei, Min Wang, Xiaolin Sang, et al.. (2019). MYC status as a determinant of synergistic response to Olaparib and Palbociclib in ovarian cancer. EBioMedicine. 43. 225–237. 58 indexed citations
17.
Song, Chengli, Lina Wang, Xiaoyan Wu, et al.. (2018). PML Recruits TET2 to Regulate DNA Modification and Cell Proliferation in Response to Chemotherapeutic Agent. Cancer Research. 78(10). 2475–2489. 28 indexed citations
18.
19.
Gang, Xiaokun, Yinhui Yang, Jian Zhong, et al.. (2016). P300 acetyltransferase regulates fatty acid synthase expression, lipid metabolism and prostate cancer growth. Oncotarget. 7(12). 15135–15149. 44 indexed citations
20.
Song, Chengli, Qiang Xu, Kui Jiang, et al.. (2015). Inhibition of BMK1 pathway suppresses cancer stem cells through BNIP3 and BNIP3L. Oncotarget. 6(32). 33279–33289. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yu-Ping Liao Breakdown of academic impact, for papers by Haiyan Dai Breakdown of academic impact, for papers by ME Sherman Breakdown of academic impact, for papers by Yunlim Kim Breakdown of academic impact, for papers by Hiroe Nakamura Breakdown of academic impact, for papers by Weifang Zhang Breakdown of academic impact, for papers by Aušra Sasnauskienė Breakdown of academic impact, for papers by Abhilasha Sinha
Rankless by CCL
2026